226 related articles for article (PubMed ID: 26994091)
1. A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F;
J Antimicrob Chemother; 2016 Jul; 71(7):1982-6. PubMed ID: 26994091
[TBL] [Abstract][Full Text] [Related]
2. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F;
J Antimicrob Chemother; 2016 Jul; 71(7):1987-93. PubMed ID: 26994089
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
Milinkovic A; Benn P; Arenas-Pinto A; Brima N; Copas A; Clarke A; Fisher M; Schembri G; Hawkins D; Williams A; Gilson R;
J Antimicrob Chemother; 2017 Jun; 72(6):1760-1768. PubMed ID: 28369381
[TBL] [Abstract][Full Text] [Related]
5. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Diaz-Brito V; León A; Knobel H; Peraire J; Domingo P; Clotet B; Dalmau D; Cruceta A; Arnaiz JA; Gatell JM; García F;
Antivir Ther; 2012; 17(2):337-46. PubMed ID: 22293542
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
McAllister JW; Towns JM; Mcnulty A; Pierce AB; Foster R; Richardson R; Carr A
AIDS; 2017 Jun; 31(9):1291-1295. PubMed ID: 28301425
[TBL] [Abstract][Full Text] [Related]
7. PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.
Fätkenheuer G; Jessen H; Stoehr A; Jung N; Jessen AB; Kümmerle T; Berger M; Bogner JR; Spinner CD; Stephan C; Degen O; Vogelmann R; Spornraft-Ragaller P; Schnaitmann E; Jensen B; Ulmer A; Kittner JM; Härter G; Malfertheiner P; Rockstroh J; Knecht G; Scholten S; Harrer T; Kern WV; Salzberger B; Schürmann D; Ranneberg B
HIV Med; 2016 Jun; 17(6):453-9. PubMed ID: 27166295
[TBL] [Abstract][Full Text] [Related]
8. Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.
Malinverni S; Bédoret F; Bartiaux M; Gilles C; De Wit S; Libois A
Sex Transm Infect; 2021 Aug; 97(5):329-333. PubMed ID: 33106437
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, the Immunological Impact, and the Effect on HIV
Leal L; Guardo AC; Bedoya LM; Rodríguez de Miguel C; Climent N; Rovira C; Beltrán M; Llach J; Alcamí J; Kashuba ADM; Gatell JM; Plana M; García F
AIDS Res Hum Retroviruses; 2023 May; 39(5):211-221. PubMed ID: 36416229
[TBL] [Abstract][Full Text] [Related]
10. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
Nagot N; Kankasa C; Meda N; Hofmeyr J; Nikodem C; Tumwine JK; Karamagi C; Sommerfelt H; Neveu D; Tylleskär T; Van de Perre P;
BMC Infect Dis; 2012 Oct; 12():246. PubMed ID: 23039034
[TBL] [Abstract][Full Text] [Related]
12. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
[TBL] [Abstract][Full Text] [Related]
13. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.
; Boyd MA; Kumarasamy N; Moore CL; Nwizu C; Losso MH; Mohapi L; Martin A; Kerr S; Sohn AH; Teppler H; Van de Steen O; Molina JM; Emery S; Cooper DA
Lancet; 2013 Jun; 381(9883):2091-9. PubMed ID: 23769235
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
Valin N; Fonquernie L; Daguenel A; Campa P; Anthony T; Guiguet M; Girard PM; Meyohas MC
BMC Infect Dis; 2016 Nov; 16(1):718. PubMed ID: 27894270
[TBL] [Abstract][Full Text] [Related]
15. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.
Foster R; McAllister J; Read TR; Pierce AB; Richardson R; McNulty A; Carr A
Clin Infect Dis; 2015 Oct; 61(8):1336-41. PubMed ID: 26123937
[TBL] [Abstract][Full Text] [Related]
16. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
Stellbrink HJ; Le Fevre E; Carr A; Saag MS; Mukwaya G; Nozza S; Valluri SR; Vourvahis M; Rinehart AR; McFadyen L; Fichtenbaum C; Clark A; Craig C; Fang AF; Heera J
AIDS; 2016 May; 30(8):1229-38. PubMed ID: 26854810
[TBL] [Abstract][Full Text] [Related]
17. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B;
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
19. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
Nelson M; Girard PM; Demasi R; Chen L; Smets E; Sekar V; Lavreys L
J Antimicrob Chemother; 2010 Jul; 65(7):1505-9. PubMed ID: 20498120
[TBL] [Abstract][Full Text] [Related]
20. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
